ライフサイエンスコーパス: preclinical model

1 ur most relevant candidate was assessed in a preclinical model.

2 ced postoperative pain in vivo with a rodent preclinical model.

3 ldefluor negative cancer cells from the same preclinical model.

4 et, off-tumor toxicity can be studied in our preclinical model.

5 hea Valve Technologies, Santa Cruz, CA) in a preclinical model.

6 ated with changes in the gut microbiota in a preclinical model.

7 at both oral cancer metastasis and pain in a preclinical model.

8 mor masses was successfully carried out on a preclinical model.

9 gy associated with painful oral cancers in a preclinical model.

10 HDACi in glioblastoma and pancreatic cancer preclinical models.

11 ion of TP53/MDM2 pathway, in HCC tissues and preclinical models.

12 flammation, and tumor lipid heterogeneity in preclinical models.

13 markable effects in limiting autoimmunity in preclinical models.

14 e and duration of EGFR inhibitor response in preclinical models.

15 oducible features for mechanistic studies in preclinical models.

16 rvivin, effectively kills many carcinomas in preclinical models.

17 tion with chemotherapy, prolongs survival in preclinical models.

18 tastatic outgrowth and prolonged survival in preclinical models.

19 stem and the impact of novel therapeutics in preclinical models.

20 d significantly prolong survival in multiple preclinical models.

21 cancer research, there is a lack of valuable preclinical models.

22 does not sustain regression in neuroblastoma preclinical models.

23 se-response relationship or tachyphylaxis in preclinical models.

24 tivity to tumors and extends survival in GBM preclinical models.

25 argets whose modulation has shown promise in preclinical models.

26 e brain and implicated in social behavior in preclinical models.

27 vasion, and prevents metastatic spreading in preclinical models.

28 s a therapy for preterm labor: evidence from preclinical models.

29 iomarker than GlcCer for neuronopathic GD in preclinical models.

30 h better than either single agent in several preclinical models.

31 therapy with rituximab enhanced activity in preclinical models.

32 ave been shown to be safe and immunogenic in preclinical models.

33 rly detection and the study of metastasis in preclinical models.

34 glucagon-like peptide-1 receptor agonists in preclinical models.

35 ndamental translational value of the current preclinical models.

36 or its effects on breast CSC activity in ER+ preclinical models.

37 tyrosine kinase-targeted tumor detection in preclinical models.

38 drug with documented anticancer activity in preclinical models.

39 binoids has been challenging to implement in preclinical models.

40 iates inflammation in an extensive number of preclinical models.

41 imited by a lack of suitable immunocompetent preclinical models.

42 ssion and confers antidepressant efficacy in preclinical models.

43 After establishment of this preclinical model, a cohort of tumor-bearing mice were i

44 In this preclinical model, a novel, high-current low-density rad

45 Utilization of proper preclinical models accelerates development of immunother

46 for treating rapidly evolving tumors through preclinical modeling and single-cell analyses.

47 Herein, we review learnings from preclinical modelling and clinical studies relating to t

48 ntrol the response to checkpoint blockade in preclinical models and are associated with better overal

49 r have been used for cancer immunotherapy in preclinical models and are currently being evaluated in

50 -2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials.

51 oration (EP) have shown promising results in preclinical models and are evaluated in clinical trials.

52 h 1 (PD1) can result in tumour regression in preclinical models and can improve anticancer T cell res

53 essly progressive and irreversible, but both preclinical models and clinical trials in various organ

54 activity, which have demonstrated safety in preclinical models and clinical trials.

55 r, with therapeutic efficacy demonstrated in preclinical models and clinical trials.

56 utic strategies can now be rapidly tested in preclinical models and effectively translated to the cli

57 ing alignment of immunological timescales in preclinical models and humans, and the use of current an

58 its strong cellular and humoral responses in preclinical models and humans.

59 namics readouts to monitor their efficacy in preclinical models and in HD patients.

60 isting in interpretation of SD-OCT images in preclinical models and in human RP.

61 for the treatment of chronic inflammation in preclinical models and in patients afflicted with chroni

62 ng approaches that are undergoing testing in preclinical models and in patients or that have received

63 hanism for resistance to anti-PD1 therapy in preclinical models and in patients with disease progress

64 re to respond to checkpoint blockade in both preclinical models and melanoma patients.

65 nergy imbalance, with significant results in preclinical models and more limited results in the clini

66 the graft is perfused, have shown benefit in preclinical models and nonrandomized clinical trials.

67 ated in influencing therapeutic responses in preclinical models and patient cohorts.

68 the progression of pulmonary hypertension in preclinical models and potentially to also assess respon

69 ctivators have been identified and tested in preclinical models, and a small number have entered clin

70 In preclinical models, androgen blockade (AB) increases exp

71 s emerging form of transplantation, adequate preclinical models are a necessity.

72 drug resistance, but most therapy-resistant preclinical models are generated in conditions that lack

73 Accurate and reproducible immune competent preclinical models are key to understanding mechanisms o

74 Notwithstanding, preclinical models are needed to understand NASH pathoph

75 e eicosanoid profile in COVID-19 patients or preclinical models are pivotal in providing novel insigh

76 Thus, reliable and integrated preclinical models are required to elucidate the mechani

77 mate 5 (mGlu5) receptor has shown promise in preclinical models as a target to reduce drinking-relate

78 ators (NAMs) have shown promising results in preclinical models but have so far failed in human clini

79 ecognized for antidepressant-like actions in preclinical models, but have not been evaluated for prop

80 tive neuroprotectants have been evaluated in preclinical models, but not one has entered the clinical

81 AAV) vectors have shown promising results in preclinical models, but the genomic consequences of tran

82 elective, efficacious, and well tolerated in preclinical models, but the high human intrinsic clearan

83 elective, efficacious, and well tolerated in preclinical models, but the high human intrinsic clearan

84 monitor Staphylococcus aureus infections in preclinical models by employing bacterial reporter strai

85 ccRCC preclinical models can be grouped into three broad categ

86 s and support the translational relevance of preclinical models demonstrating a possible causal role

87 Preclinical models demonstrating sex-specific vulnerabil

88 treatment benefit was demonstrated using two preclinical models derived from patients with clear cell

89 In a preclinical model developed in our laboratory, rats exhi

90 The condition remains understudied in preclinical models due to its delayed presentation.

91 es together with loss-of-function studies in preclinical models established the importance of RUNX1 a

92 23414 demonstrates efficacy against EAC in a preclinical model, establishing the rationale for clinic

93 logically relevant gluten- and HLA-dependent preclinical model exists.

94 of astrocytes in multiple sclerosis and its preclinical model experimental autoimmune encephalomyeli

95 linked mouse (mdx) is the most commonly used preclinical model for Duchenne muscular dystrophy.

96 and provide a transcriptional dataset and a preclinical model for further investigating SCCB biology

97 infection of rhesus monkeys is an important preclinical model for human immunodeficiency virus type

98 the Rds/Prph2 (P216L) transgenic mouse as a preclinical model for retinitis pigmentosa.

99 Cre;ndufs4(loxP/loxP) mouse line a promising preclinical model for testing therapies for currently un

100 To establish a preclinical model for therapeutic inhibition of putative

101 nsequently, we have characterised a panel of preclinical models for their SSTR2 expression, in vivo g

102 introduce a conceptual framework for use of preclinical models for therapeutic development.

103 d compounds was successfully demonstrated on preclinical model goat heart mitochondria, in vitro.

104 ing (QSM) technique to prediction of SPIO in preclinical models has been challenging due to a large v

105 Since then, establishing safety in preclinical models has been one of the major challenges

106 tation of hPSC-derived cell populations into preclinical models has generated teratomas (tumors arisi

107 ammatories, and discuss how their success in preclinical models has paved the way for clinical trials

108 ed in the cotton rat and the mouse, and both preclinical models have been routinely used to evaluate

109 igh-fidelity control of neuronal activity in preclinical models have begun to elucidate the contribut

110 Preclinical models have demonstrated that nitric oxide i

111 micro-dystrophin delivery or exon skipping, preclinical models have shown that incomplete restoratio

112 In vitro and in preclinical models, HDL can preserve beta-cell function,

113 oprotective and anti-inflammatory effects in preclinical models, highlight the potential of this arma

114 e EVAs potently inhibit inflammation in many preclinical models, highlighting their potential as biol

115 In preclinical models, host LGP2 was essential for optimal

116 in diseases are supported by data from many preclinical models, human genetic studies, and clinical

117 ccination and should be further evaluated in preclinical models.IMPORTANCE Human cytomegalovirus (HCM

118 Dose selection was guided by a preclinical model in mice and nonhuman primates that rel

119 mutation predicted sensitivity to NSAIDs in preclinical models in association with increased systemi

120 provides insights into the usefulness of the preclinical models in enabling pharmacokinetic optimizat

121 PCa) tumor growth as monotherapy in multiple preclinical models in mice and shows synergistic antitum

122 sion of Acan and other anabolic genes in two preclinical models in vivo.

123 s for HGSC has been hampered by a paucity of preclinical models in which new drugs could be tested fo

124 ients and explored the mechanism in relevant preclinical models including patient-derived xenografts.

125 treating ROS1- or NTRK-rearranged cancer in preclinical models, including crizotinib-resistant ROS1

126 on of trained immunity protected mice in all preclinical models, including when training and infectio

127 sms underlying AD and provides evidence that preclinical models incorporating genetic diversity may b

128 Opioid administration in preclinical models induces long-lasting adaptations in r

129 ect on the clinical lupus parameters in this preclinical model, inhibitors of SphK2 might not be usef

130 Tolerance in our preclinical model is associated with a regulatory networ

131 re nonexistent, and the development of a new preclinical model is crucial.

132 rcinoma, and notwithstanding cohort size and preclinical model limitations, the data suggest that tum

133 In preclinical models, LV unloading reduced the expression

134 Preclinical models more reflective of human pathophysiol

135 Using a preclinical model of adolescent THC exposure in male rat

136 Our work thus defines a new preclinical model of AIS and provides tools to realize n

137 d by the lack of a physiologically relevant, preclinical model of allogeneic HSCT.

138 tively, these tests constitute a predominant preclinical model of anxiety disorder.

139 PDGFRbeta(D849V) in their stromal cells as a preclinical model of breast cancer-associated brain meta

140 ted sodium channel Nav1.7 are increased in a preclinical model of chemotherapy-induced peripheral neu

141 uppressed tumor development effectively in a preclinical model of colorectal cancer.

142 The sum of our results in a preclinical model of disease suggest that replacement of

143 apy using radiolabeled DOTA-daratumumab in a preclinical model of disseminated multiple myeloma.

144 gical inhibitors of MRTF/SRF signalling in a preclinical model of fibrosis.

145 sgenic rats (Fmr1-KO rats) as an alternative preclinical model of FXS.

146 We developed a new preclinical model of group 2 PH by combining MetS with L

147 rroborate the viability of the marmoset as a preclinical model of human MFC dysfunction, and suggest

148 recently targeted as a potentially powerful preclinical model of human prefrontal cortex dysfunction

149 This preclinical model of hypertension exhibits a sex-depende

150 In a preclinical model of kidney injury, paricalcitol inhibit

151 Here, using a preclinical model of limited voluntary drug use in rats,

152 over intra-arterial drug administration in a preclinical model of liver cancer.

153 Our study provides a robust rodent preclinical model of LRRK2-linked PD and nominates kinas

154 on of metastasis-associated macrophages in a preclinical model of lung metastasis.

155 e-related peptide receptor antagonists, in a preclinical model of medication overuse.

156 or PET imaging of fibroblast activation in a preclinical model of MI.

157 mental autoimmune encephalomyelitis (EAE), a preclinical model of MS, in preventive and therapeutic s

158 ffect induced by anti-Sema4D antibodies in a preclinical model of neuroendocrine pancreatic cancer (R

159 antitumor efficacy of (67)Cu-CuSarTATE in a preclinical model of neuroendocrine tumors and compare i

160 that the exacerbated expression of Cdk5 in a preclinical model of neuropathic pain increases the func

161 den while improving intestinal function in a preclinical model of ovarian cancer metastasis.

162 -induced muscle wasting and dysfunction in a preclinical model of pancreatic ductal adenocarcinoma (P

163 ng haloperidol induced catalepsy in a rodent preclinical model of Parkinson's disease.

164 Here, we develop a robust preclinical model of PD in adult rats induced by the bra

165 d biologic-like efficacy in an IL-23-induced preclinical model of psoriasis.

166 epeated application of imiquimod, which is a preclinical model of psoriasis.

167 plore the safety of TPIAT in PDAC in a mouse preclinical model of subcutaneous xenotransplantation of

168 but its deletion enhances remyelination in a preclinical model of the human demyelinating disease mul

169 tomical and functional outcome measures in a preclinical model of traumatic spinal cord injury (SCI).

170 We used a preclinical model of uropathogenic Escherichia coli-indu

171 es) and rodent models (e.g., rats, mice) for preclinical modeling of the human brain in healthy and d

172 However, the effect of mTOR inhibitors in preclinical models of acquired epilepsy is inconsistent.

173 -brain barrier, and reduced infarct size, in preclinical models of acute ischaemic stroke, and showed

174 l stromal cells (MSCs) has shown benefits in preclinical models of acute respiratory distress syndrom

175 f current standard-of-care chemotherapies in preclinical models of advanced pancreatic and ovarian ca

176 tic therapy approaches have been explored in preclinical models of AF, and offer potential as a treat

177 rgprb2 deficiency decreased itch in multiple preclinical models of allergic contact dermatitis (ACD),

178 Preclinical models of Alzheimer's disease (AD) suggest A

179 ived from a traditional Chinese medicine, in preclinical models of asthma.

180 fects of cortistatin in two well-established preclinical models of atherosclerosis, and the molecular

181 Furthermore, efficacy of 14a in multiple preclinical models of autoimmune diseases are presented.

182 We developed preclinical models of bone marrow transplantation (BMT)

183 However, the paucity of robust preclinical models of brain metastasis has severely limi

184 n total, this work presents resources of new preclinical models of breast cancer with large mRNA-seq

185 ablished cell- and patient-derived xenograft preclinical models of breast cancer, providing a potenti

186 y in vitro and in vivo, including in various preclinical models of CDI.

187 With the use of three different preclinical models of colorectal cancer, we also discove

188 of preventive strategies was demonstrated in preclinical models of colorectal cancer.

189 d IL-17A blockade curbs tumor progression in preclinical models of CRC.

190 er disease states and are neuroprotective in preclinical models of critical illness.

191 The imaging readouts can be obtained in both preclinical models of diabetes mellitus and patients wit

192 stages of diabetes using fundus images from preclinical models of diabetes.

193 ion and (13)C probes investigated to date in preclinical models of disease.

194 the ways these inhibitors have been used in preclinical models of diseases.

195 demonstrate effective antitumor activity in preclinical models of DLBCL associated with replication

196 apigenin has multiple therapeutic targets in preclinical models of DS.

197 several recent reports of genome editing in preclinical models of Duchenne muscular dystrophy(1-6),

198 the therapeutic potential of ELNs induction, preclinical models of ELNs are needed for interrogation

199 tionale for future studies targeting Ncad in preclinical models of EOC metastasis.

200 nesis has shown promising results in several preclinical models of Ewing sarcoma and osteosarcoma.

201 ion was increased after anti-VEGF therapy in preclinical models of GBM.

202 r (AR) activity that has been established in preclinical models of HCC with the clinical failure of A

203 he cytotoxicity of targeted Auger therapy in preclinical models of high-risk neuroblastoma.

204 lopment, there is a crucial need for in vivo preclinical models of human biology and pathology.

205 inhibited disease progression in aggressive preclinical models of human cancers and induced cell kil

206 a roadmap for the development of predictive preclinical models of human DILI.

207 validation of MALT1 allosteric inhibition in preclinical models of humoral immune responses and B-cel

208 nity provides protection in a large panel of preclinical models of infections.

209 g protein, has beneficial effects in diverse preclinical models of inflammation and injury.

210 ective in the alleviation of inflammation in preclinical models of inflammatory bowel disease, at lea

211 Studies in preclinical models of influenza virus infections have sh

212 iopsies from patients with active IBD and in preclinical models of intestinal inflammation.

213 ut has not been previously tested in cell or preclinical models of intestinal tumorigenesis.

214 utic potential of targeting Wnt signaling in preclinical models of intestinal-type gastric cancer and

215 he efficacy of MEK-ERK inhibition in various preclinical models of KRAS-driven cancers, providing a r

216 tidrug resistant leukemia phenotype based on preclinical models of leukemia, providing the framework

217 miRNAs suppressed metastatic colonization in preclinical models of lung and liver metastasis and corr

218 but have yet to be evaluated in stress-based preclinical models of MDD.

219 of cue-reactivity screening models and even preclinical models of medication development.

220 systems-level analyses of decision making in preclinical models of mental illness.

221 d the clearance of P-bodies and autophagy in preclinical models of metastasis, arresting cancer cells

222 In preclinical models of NASH, praliciguat treatment was as

223 en shown to have a neuroprotective effect in preclinical models of neonatal brain injury, and phase 2

224 atively improving translational relevance of preclinical models of neuropsychiatric diseases.

225 mechanistically interrogate this network in preclinical models of neuropsychiatric disorders.

226 ucose homeostasis and reduces food intake in preclinical models of obesity and diabetes.

227 ith aggressive B cell lymphoma as well as in preclinical models of other malignancies.

228 Robust preclinical models of ovarian high-grade serous carcinom

229 Using preclinical models of patient-derived xenografts and 3-d

230 ogenesis, all of which are also increased in preclinical models of PPBC.

231 Preclinical models of prenatal inflammation have been de

232 Preclinical models of psychosis propose that hippocampal

233 hibitors have shown therapeutic potential in preclinical models of psychostimulant abuse.

234 Based on synergy in preclinical models of PTCL, we initiated a phase 1 study

235 We evaluated evobrutinib in preclinical models of RA and SLE and characterized the r

236 selective ROS1/NTRK inhibitor, DS-6051b, in preclinical models of ROS1- or NTRK-rearranged cancers.

237 In preclinical models of solid tumors, both pro-metastatic

238 In preclinical models of spontaneous metastasis, BMP4 acted

239 antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD.

240 Here, we found that onset of autoimmunity in preclinical models of T1D is associated with alterations

241 o, allowing creation of genetically accurate preclinical models of these disorders.

242 Preclinical models of threat conditioning and extinction

243 PORCN inhibitors show efficacy in preclinical models of Wnt-addicted cancers, including RN

244 to effectively suppress pineoblastoma in our preclinical models, offering new modality for this letha

245 Genetic ablation of Epha2 or Ptgs2 in preclinical models or pharmacological inhibition of COX-

246 e-risk potential negative cardiac effects in preclinical models, our data support the therapeutic str

247 In a preclinical model, pacemaker-induced cardiomyopathy can

248 ogical tools to study anti-ZIKV responses in preclinical models, particularly T cell responses, remai

249 acid nanoparticles (NANPs) using a validated preclinical model, peripheral blood mononuclear cells (P

250 In preclinical models, peripherally restricted cannabinoid

251 F-NOTA-OC were then used to quantify bias of preclinical model predictions versus clinical measuremen

252 bition significantly reduces tumor growth in preclinical models, providing strong rationale for targe

253 We demonstrate that our preclinical model recapitulates the cardio-respiratory d

254 ) TILs after combined Tim-3+PD-1 blockade in preclinical models revealed significant changes in the t

255 ed by medications to reduce cocaine relapse, preclinical models should consider polysubstance use.

256 Preclinical models show that Scl-Ab administration prese

257 Previous studies in preclinical models showed that pre-menopausal levels of

258 port the view that marmosets are a promising preclinical modeling species for studying LFC dysfunctio

259 However, the efficacy of HT in preclinical models, such as the Vannucci model of unilat

260 Preclinical models suggest that combining BRAF and MEK i

261 Furthermore, studies in preclinical models suggest that decreasing IL-6 activity

262 ted osteolysis and metastatic progression in preclinical models, suggesting a new treatment opportuni

263 epigenetic pathway showed potent efficacy in preclinical models, suggesting key therapeutic targets f

264 Preclinical modeling suggests that intermittent BRAF inh

265 nded trials in major depression, and whether preclinical models tell us much about novel drug develop

266 mechanism and provides proof of concept in a preclinical model that FICZ-mediated AHR pathway activat

267 In addition to developing a preclinical model that phenocopies exudative AMD, our st

268 ble quantitative histopathologic analyses in preclinical models that also might be applicable to clin

269 l of new anticancer therapies is the lack of preclinical models that can be used to identify key mole

270 -modifying therapies for CMML, nor are there preclinical models that fully recapitulate the unique fe

271 In chronic GVHD preclinical models that have a pathophysiology distinct

272 of death in the developed world, yet facile preclinical models that mimic the natural stages of CRC

273 or xenografts (PDX) have emerged as reliable preclinical models that more accurately recapitulate tum

274 ith HR(+) BC, in part reflecting the lack of preclinical models that recapitulate disease progression

275 A dearth of preclinical models that recapitulate the metastatic micr

276 Preclinical models that reliably recapitulate the immuno

277 We report in a preclinical model the absence of local and distant sprea

278 Based on the phenotypes of our preclinical models, the FLCN H255Y mutant protein has lo

279 nce to BET inhibitors has been documented in preclinical models, the molecular mechanisms underlying

280 ng the multimammate mouse Mastomys coucha as preclinical model, this is the first study demonstrating

281 neered to mediate tumor clearance in vivo in preclinical models through Fc-FcgammaR interactions.

282 wn to sensitize solid tumors to radiation in preclinical models through localized insult to the vascu

283 NHPs can therefore be used as a preclinical model to develop HCV vaccines.

284 Here we employ a preclinical model to identify the therapeutic targets of

285 dentifies a new and widely accessible simple preclinical model to recreate and explore underpinning p

286 increasing need for advanced and inexpensive preclinical models to accelerate the development of anti

287 we used N-terminomic proteomic profiling in preclinical models to elucidate the in vivo repertoire o

288 rapies in TBI and the use and limitations of preclinical models to explore these therapies.

289 istance, people have successfully tested, in preclinical models, treatments targeting specific resist

290 e we review the strengths and limitations of preclinical models used for these purposes and describe

291 ed to measure functional MKP-1 induction and preclinical models using Aggregatibacter actinomycetemco

292 ective radiosensitizing agents in a range of preclinical models using broad field sources of various

293 ransplantation and patient-derived xenograft preclinical models, we defined clear functions for CDK4

294 Using patient samples and preclinical models, we objectively quantified DDX3 and A

295 Using preclinical models, we show that RMC-4550, an allosteric

296 Our results suggest that this preclinical model will allow testing of novel complement

297 Our findings provide a preclinical model with which to test the causal associat

298 these obstacles, but requires assessment in preclinical models with the capacity to respond to both

299 Our novel preclinical model would accelerate the testing of therap

300 a vital neurovascular signalling molecule in preclinical models, yet the mechanisms underlying neurov